-+ 0.00%
-+ 0.00%
-+ 0.00%

NextCure reports 55% response rate in Phase 1 SIM0505 trial in gynecologic cancers at ASCO 2026

PUBT·06/01/2026 12:08:44
Listen to the news
NextCure reports 55% response rate in Phase 1 SIM0505 trial in gynecologic cancers at ASCO 2026
  • NextCure reported positive early-stage results for SIM0505, an experimental antibody-drug conjugate for gynecologic cancers, presented at ASCO 2026.
  • The study showed meaningful tumor shrinkage signals in heavily pretreated ovarian cancer and uterine serous carcinoma patients within the targeted dose range.
  • Safety looked manageable overall, supporting continued Phase 1 dose optimization with a strategic focus on platinum-resistant ovarian cancer.
  • A virtual key opinion leader event is scheduled for June 2, 2026 to review the ASCO data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.